Efficacy and safety of levetiracetam: An add-on trial in children with refractory epilepsy

The aim of this multicentric, prospective and uncontrolled study was to evaluate the efficacy and safety of Levetiracetam in 110 children with refractory epilepsy, of whom 21 were less than 4 years old. After a median follow-up period of 7 months, Levetiracetam administration was effective (responders with >50% decrease in seizure frequency) in 39% of children, of whom 10 (9%) became seizure-free. The efficacy was higher in patients with Localization - related epilepsy (58% of responders) than in those with generalized epilepsy (37% of responders). Levetiracetam was well tolerated. The main side effects of somnolence and irritability occurred in 14% of patients. In one patient acute choreoathetosis occurred after few doses of levetiracetam. Overall, the adverse effects were not severe. Children younger than 4 years were particularly tolerant. In conclusion, the present study confirms that levetiracetam is effective and well tolerated as an add-on treatment in children with refractory epilepsy. Our preliminary data also indicate that Levetiracetam may be a valid therapeutic option for epilepsy in infants and young children. (C) 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.